Osimertinib: beside a new treatment under test
105 studies: a new drug, cell therapy or vaccine is what the study tests. Page 2 of 2. Open to participants first (45), then studies with results posted, then the rest; newest registration first within each.
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingNCT03040973Phase 2How we knowReport a problem
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2How we knowReport a problem
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT02520778Phase 1How we knowReport a problem
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02503722Phase 1How we knowReport a problem
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingNCT02099058Phase 1How we knowReport a problem